Using Sugar to Detect Malignant Tumors
News Feb 24, 2016
"If sugar replaces metal as a contrast agent in the body, it can also have a positive psychological effect and make patients calmer," says Linda Knutsson, senior lecturer at Lund University in Sweden.
A tumour's properties can be examined by injecting a small amount of sugar into it, and then measuring how much sugar the tumour consumes. The more sugar the tumour consumes, the more malignant it is.
Linda Knutsson is working with a team from Johns Hopkins University in the USA, which has developed a new imaging technique for magnetic resonance tomography. The collaboration has resulted in the new imaging technique being combined with the testing of natural sugar as a replacement for metal in contrast agents.
There is no similar clinical research in this area. It is the first time a non-synthetic contrast agent has been used in human magnetic resonance tomography examinations, and the results are promising. The uptake of sugar is higher in the tumour than in healthy tissue according to the results of tests carried out by Linda Knutsson and the Johns Hopkins team in the USA. The tests were carried out on three persons with a brain tumour and four healthy persons and published in the research journal Tomography in December last year. A more detailed study on a large group of patients is to commence soon in Lund.
"Metal-based contrast agents cost more than sugar-based agents. Accordingly, this could lead to a reduction in medical care costs," says Linda Knutsson.
A disadvantage is that sugar-based contrast agents cannot be used in examinations of diabetes patients.
Smart Phone Developed for Quicker Infection TestingNews
Washington State University researchers have developed a low-cost, portable laboratory on a phone that works nearly as well as clinical laboratories to detect common viral and bacterial infections.READ MORE
New Rapid-fire Method Using Pathology Images & Tumor Data May Help Guide Cancer TherapiesNews
By combining data on pathology images of 13 types of cancer and correlating that with clinical and genomic data, researchers are able to identify tumor-infiltrating lymphocytes, which will enable cancer specialists to generate tumor-immune information from routinely gathered pathology slides.READ MORE
Comments | 0 ADD COMMENT
6th International Conference on Neurodegenerative Disorders and Stroke
Oct 22 - Oct 23, 2018
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018